Tags

Type your tag names separated by a space and hit enter

Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy.
Exp Biol Med (Maywood). 2010 Nov; 235(11):1338-46.EB

Abstract

Favorable effects of angiotensin II type 1 receptor blockers on patients with ischemic or idiopathic dilated cardiomyopathy (DCM) have already been suggested by several human trials, but their effects on DCM remain unknown. Hence, we investigated the effect of olmesartan on myocardial remodeling in a rat model in which myosin-induced experimental autoimmune myocarditis (EAM) might develop into DCM. EAM was elicited in Lewis rats by immunization with cardiac myosin, and 28 d after immunization, the surviving Lewis rats were divided into two groups and treated with either olmesartan (10 mg/kg/d) or vehicle. Age-matched normal rats without immunizations were also used. After four weeks of treatment, we investigated the effects of olmesartan on cardiac function, inflammatory cytokines and cardiac remodeling in EAM rats. Myocardial functional parameters measured by hemodynamic and echocardiographic analyses were significantly improved by the treatment with olmesartan compared with those of vehicle-treated rats. Olmesartan significantly reduced cardiac fibrosis as well as hypertrophy and its molecular markers (left ventricular [LV] mRNA expressions of transforming growth factor beta1, collagen-I and -III, and atrial natriuretic peptide) compared with those of vehicle-treated rats. Increased myocardial mRNA expressions of proinflammatory cytokines (interleukin [IL]-6, IL-1β), monocyte chemoattractant protein-1 and matrix metalloproteinases (MMP-2 and -9) were also suppressed by the treatment with olmesartan in rats with DCM. Further, the plasma level of angiotensin II was significantly increased in olmesartan-treated rats. These findings demonstrate that olmesartan treatment significantly improved LV function and ameliorated the progression of cardiac remodeling in rats with DCM after EAM.

Authors+Show Affiliations

Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City 956-8603.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20876084

Citation

Sukumaran, Vijayakumar, et al. "Beneficial Effects of Olmesartan, an Angiotensin II Receptor Type 1 Antagonist, in Rats With Dilated Cardiomyopathy." Experimental Biology and Medicine (Maywood, N.J.), vol. 235, no. 11, 2010, pp. 1338-46.
Sukumaran V, Watanabe K, Veeraveedu PT, et al. Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy. Exp Biol Med (Maywood). 2010;235(11):1338-46.
Sukumaran, V., Watanabe, K., Veeraveedu, P. T., Thandavarayan, R. A., Gurusamy, N., Ma, M., Yamaguchi, K., Suzuki, K., Kodama, M., & Aizawa, Y. (2010). Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy. Experimental Biology and Medicine (Maywood, N.J.), 235(11), 1338-46. https://doi.org/10.1258/ebm.2010.010016
Sukumaran V, et al. Beneficial Effects of Olmesartan, an Angiotensin II Receptor Type 1 Antagonist, in Rats With Dilated Cardiomyopathy. Exp Biol Med (Maywood). 2010;235(11):1338-46. PubMed PMID: 20876084.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy. AU - Sukumaran,Vijayakumar, AU - Watanabe,Kenichi, AU - Veeraveedu,Punniyakoti T, AU - Thandavarayan,Rajarajan A, AU - Gurusamy,Narasimman, AU - Ma,Meilei, AU - Yamaguchi,Ken'ichi, AU - Suzuki,Kenji, AU - Kodama,Makoto, AU - Aizawa,Yoshifusa, Y1 - 2010/09/27/ PY - 2010/9/30/entrez PY - 2010/9/30/pubmed PY - 2010/12/14/medline SP - 1338 EP - 46 JF - Experimental biology and medicine (Maywood, N.J.) JO - Exp Biol Med (Maywood) VL - 235 IS - 11 N2 - Favorable effects of angiotensin II type 1 receptor blockers on patients with ischemic or idiopathic dilated cardiomyopathy (DCM) have already been suggested by several human trials, but their effects on DCM remain unknown. Hence, we investigated the effect of olmesartan on myocardial remodeling in a rat model in which myosin-induced experimental autoimmune myocarditis (EAM) might develop into DCM. EAM was elicited in Lewis rats by immunization with cardiac myosin, and 28 d after immunization, the surviving Lewis rats were divided into two groups and treated with either olmesartan (10 mg/kg/d) or vehicle. Age-matched normal rats without immunizations were also used. After four weeks of treatment, we investigated the effects of olmesartan on cardiac function, inflammatory cytokines and cardiac remodeling in EAM rats. Myocardial functional parameters measured by hemodynamic and echocardiographic analyses were significantly improved by the treatment with olmesartan compared with those of vehicle-treated rats. Olmesartan significantly reduced cardiac fibrosis as well as hypertrophy and its molecular markers (left ventricular [LV] mRNA expressions of transforming growth factor beta1, collagen-I and -III, and atrial natriuretic peptide) compared with those of vehicle-treated rats. Increased myocardial mRNA expressions of proinflammatory cytokines (interleukin [IL]-6, IL-1β), monocyte chemoattractant protein-1 and matrix metalloproteinases (MMP-2 and -9) were also suppressed by the treatment with olmesartan in rats with DCM. Further, the plasma level of angiotensin II was significantly increased in olmesartan-treated rats. These findings demonstrate that olmesartan treatment significantly improved LV function and ameliorated the progression of cardiac remodeling in rats with DCM after EAM. SN - 1535-3699 UR - https://www.unboundmedicine.com/medline/citation/20876084/Beneficial_effects_of_olmesartan_an_angiotensin_II_receptor_type_1_antagonist_in_rats_with_dilated_cardiomyopathy_ L2 - https://journals.sagepub.com/doi/10.1258/ebm.2010.010016?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -